Cancer is scary but, unfortunately, not uncommon. According to the American Cancer Society report on the annual status of cancer (from the American Cancer Society, the Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Associate of Central Cancer Registries), the overall incidence rates for cancer were 497 per 100,000 male and 431 per 100,000 females for the years 2014-2018. The trend is an increase in cancer rate of 0.2% per year.
Cancer risk is multifaceted and complex, and although one can address our risk through lifestyle intervention, screening remains a powerful tool in early cancer detection. GRAIL introduced the Galleri test, which detects a signal shared by 50 types of cancer with high specificity and accuracy. It complements routine cancer screening and is ground-breaking in early detection, allowing for early intervention and treatment.
Galleri test is a blood test drawn in the office with results available in two weeks. This easily performed test can mean the detection of cancer early enough that it can be treated and a way for regular screening for high-risk individuals that goes beyond the usual screenings for breast, cervical, lung, colorectal, and prostate cancers.
To push the screening further, full-body MRI scans complement the Galleri blood test (or “liquid biopsy”) to provide prevention and early diagnosis.
Petersen Concierge Medical offers both to its clients as part of its bespoke personalized prevention healthcare.